CLINICAL AND HISTOLOGIC FEATURES OF UTERINE MYOMA IN REPRODUCTIVE-AGE WOMEN UNDER THE TREATMENT BY SELECTIVE PROGESTERONE RECEPTOR MODULATORS

Aim of the study was to investigate the clinical features of reproductive age women with uterine body myoma and the production of vascular endothelial growth factor (VEGF) in the dominant myoma node and perifocal myometrium under the preoperative use of ulipristal acetate (UA). Material and methods. 140 samples of 35 women surgical material were studied, VEGF content in the incubation medium of samples of myoma and myometrium was measured using enzymelinked  immunosorbent assay.Results and discussion. The treatment by UA before myoma surgery according to the standard regimen per 5 mg daily for 13 weeks deals with significantly reduced production of VEGF in the dominant myoma node compared to perifocal myometrium (p < 0.001), which is similar to patients of the control group. However, when comparing tumor nodes, a significantly lower content of VEGF was revealed in the UA-group (p = 0.026); unlike the perifocal myometrium samples. Conclusion. The use of a selective modulator of progesterone receptors downregulates the production of VEGF by the cells of the myoma nodes and doesn’t impact on the perifocal myometrium

Enzyme immunoassay of interleukin content in tumor supernatants in patients with multiple uterine myoma

The aim of the study was to determine the effects of a mixture of polyclonal activators on the interleukin production by dominant myomatous and myometrial tissue samples under treating by ulipristal acetate (UA), a selective modulator of progesterone receptors.Цель работы — изучить эффект поликлональных активаторов на продукцию интерлейкинов и 17-ОН-прогестерона в ткани доминирующего миоматозного узла и перифокального миометрия в условиях применения улипристала ацетата (УА), селективного модулятора прогестероновых рецепторо